4.6 (584) In stock
Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease. The condition causes the colon and rectum to become inflamed and ulcerated.
SciELO - Brazil - TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES
Infliximab
Overview, Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy, Guidance
Infliximab
FDA Approves Subcutaneous Infliximab for IBD
Infliximab
ARCH Study: Higher Doses of Infliximab in Acute Severe Ulcerative Colitis
Pharmaceutics, Free Full-Text
Pharmaceutics, Free Full-Text
PDF) Review Article: Acute Severe Ulcerative Colitis, An Update on Optimal Medical Management
What is Infliximab (Remicade)?
Crohn's & Colitis Foundation on X: The FDA approved Celltrion USA's ZYMFENTRA® (infliximab-dyyb), the first and only subcutaneous infliximab injection, for the treatment of moderate to severe ulcerative colitis and Crohn's disease.
High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival
Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic
Management of moderate to severe ulcerative colitis - American Gastroenterological Association
